Abstract

Isoagglutinins removal by apheresis and immunosuppressive therapy are generally performed at pre-transplant desensitization of ABO-incompatible kidney transplantation. Selective plasma exchange (SePE) is a new simple plasma exchange (PE) modality that enables removal of small and medium-sized molecules without removing larger molecules, such as coagulation factors. Since 2015, we have always performed SePE using albumin solution in patients with a low isoagglutinin titers, or we added this approach in patients in whom the isoagglutinin titers was sufficiently decreased by double-filtration plasmapheresis (DFPP) and/or simple PE. However, although this procedure is advantageous in that it has fewer adverse effects, it also removes about 30% of coagulation factors, such as fibrinogen and factor XIII, and this is problematic in the perioperative period. Thus, we currently perform SePE using fresh frozen plasma (FFP) as part of the replacement fluid in patients with a decline of coagulation factors. We have had a favorable impression clinically with regard to the decline of the antibody titer with use of FFP. In this study, we examined if this impression was supported by a significant difference in outcomes.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.